Target intelligence / Profile preview

3-oxoacyl-[acyl-carrier-protein] synthase 2 (FabF)

Target
FabF
Molecular classification
Enzyme, Transferase, Acyltransferase, Beta-ketoacyl-ACP synthase family, Thiolase-like superfamily
01

Overview

3-oxoacyl-[acyl-carrier-protein] synthase 2, commonly known as FabF, is a key enzyme in the bacterial Type II fatty acid synthesis (FAS II) pathway. It catalyzes the condensation of an acyl-acyl carrier protein (ACP) with malonyl-ACP, a critical step that extends the growing fatty acid chain by two carbon units. This enzyme is essential for maintaining the structural integrity of the bacterial cell membrane and plays a specialized role in the thermal regulation of fatty acid composition. Because the FAS II system is composed of discrete enzymes and is structurally distinct from the multifunctional human Type I FAS system, FabF is considered a highly attractive target for the development of novel antibiotics. Several natural product inhibitors, including platensimycin and cerulenin, have been identified that potently inhibit FabF by binding to its active site. While these compounds show significant antibacterial activity in laboratory settings, their clinical development has been challenged by poor pharmacological properties and the potential for rapid emergence of resistance. Ongoing research aims to optimize these inhibitors to address the growing threat of multidrug-resistant bacterial infections.

Other names
3-oxoacyl-[acyl-carrier-protein] synthase IIBeta-ketoacyl-ACP synthase IIKAS IIKAS2Beta-ketoacyl-acyl carrier protein synthase II
02

Mechanism of action

Inhibition of the condensation step in the bacterial Type II fatty acid synthesis (FAS II) pathway by binding to the enzyme's active site, thereby preventing the elongation of fatty acid chains and disrupting membrane integrity.

03

Biological functions

Fatty acid biosynthesisAcyl-ACP elongationThermal regulation of fatty acid compositionCondensation of malonyl-ACP with acyl-ACP
04

Disease associations

Infection
05

Safety considerations

Potential cross-reactivity with human fatty acid synthase (FAS I)Poor cell penetration and high efflux in Gram-negative bacteriaDevelopment of bacterial resistance through mutations in the fabF gene
06

Interacting drugs

Cerulenin

6 more in the full profile.

Beyond the preview

Go deeper on 3-oxoacyl-[acyl-carrier-protein] synthase 2 (FabF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-oxoacyl-[acyl-carrier-protein] synthase 2 (FabF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call